Skip to main content
SpringerLink
Log in

Anti-HER2 et cancers du sein métastatiques: Résultats cliniques des anti-HER2 actuels et futurs

  • Conference paper
Cancer du sein

  • 545 Accesses

Résumé

Le cancer du sein HER2-positif représente 20 à 25 % de l’ensemble des cancers du sein et la surexpression de ce récepteur tyrosine kinase est classiquement associée à un mauvais pronostic [142]. Cependant, la prise en charge et le devenir de ces patientes ont considérablement changé depuis l’avènement du trastuzumab puis du lapatinib ces dix dernières années. Malgré les résultats encourageants obtenus avec ces thérapies ciblées chez les patientes métastatiques, la progression est la règle et des résistances apparaissent. Ainsi, de nombreuses autres thérapies ont fait leur apparition, avec diverses propriétés: inhibiteur pan-HER comme le pertuzumab, anti- HER2 et anti-EGFR (neratinib), anti-angiogéniques (bevacizumab, pazopanib), inhibiteurs de la voie PI3K, inhibiteurs de la protéine chaperonne hsp90, etc. (tableau I).

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Références

  1. Andre F, Campone M, O’Regan R et al. (2010) Phase I Study of Everolimus Plus Weekly Paclitaxel and Trastuzumab in Patients With Metastatic Breast Cancer Pretreated With Trastuzumab. J Clin Oncol 28: 5110–5115

    Article  PubMed  CAS  Google Scholar 

  2. Andreopoulou E, Gaiotti D, Kim E et al. (2007) Feasibility and cardiac safety of pegylated liposomal doxorubicin plus trastuzumab in heavily pretreated patients with recurrent HER2-overexpressing metastatic breast cancer. Clinical breast cancer 7: 690–696

    Article  PubMed  CAS  Google Scholar 

  3. Arnould L, Gelly M, Penault-Llorca F et al. (2006) Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism? Br J Cancer 94: 259–267

    Article  PubMed  CAS  Google Scholar 

  4. Awada A, Dirix L, Beck J et al. (2009) Safety and Efficacy of Neratinib (HKI-272) in Combination with Vinorelbine in ErbB2+ Metastatic Breast Cancer. San Antonio Breast Cancer Symposium 2009, San Antonio, Texas, US

    Google Scholar 

  5. Bartsch R, Wenzel C, Altorjai G et al. (2007) Capecitabine and trastuzumab in heavily pretreated metastatic breast cancer. J Clin Oncol 25: 3853–3858

    Article  PubMed  CAS  Google Scholar 

  6. Bartsch R, Wenzel C, Gampenrieder SP et al. (2008) Trastuzumab and gemcitabine as salvage therapy in heavily pre-treated patients with metastatic breast cancer. Cancer Chemother Pharmacol 62: 903–910

    Article  PubMed  CAS  Google Scholar 

  7. Bartsch R, Wenzel C, Pluschnig U et al. (2006) Oral vinorelbine alone or in combination with trastuzumab in advanced breast cancer: results from a pilot trial. Cancer Chemother Pharmacol 57: 554–558

    Article  PubMed  CAS  Google Scholar 

  8. Baselga J, Cortes J, Fumoleau P et al. (2009) Pertuzumab and Trastuzumab: Re-Responses to 2 Biological Agents in Patients with HER2-Positive Breast Cancer Which Had Previously Progressed during Therapy with Each Agent Given Separately: A New Biological and Clinical Observation. San Antonio Breast Cancer Symposium 2009, San Antonio, Texas, US

    Google Scholar 

  9. Baselga J, De Jonge MJ, Rodon J et al. (2010) A first-in-human phase I study of BKM120, an oral pan-class I PI3K inhibitor, in patients (pts) with advanced solid tumors. American Society of Clinical Oncology Annual Meeting; 2010; Chicago, US

    Google Scholar 

  10. Baselga J, Carbonell X, Castaneda-Soto NJ et al. (2005) Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule. J Clin Oncol 23: 2162–2171

    Article  PubMed  CAS  Google Scholar 

  11. Baselga J, Gelmon KA, Verma S et al. (2010) Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. J Clin Oncol 28: 1138–1144

    Article  PubMed  CAS  Google Scholar 

  12. Baselga J, Norton L, Albanell J, Kim YM, Mendelsohn J (1998) Recombinant humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res 58: 2825–2831

    PubMed  CAS  Google Scholar 

  13. Baselga J, Tripathy D, Mendelsohn J et al. (1999) Phase II study of weekly intravenous trastuzumab (Herceptin) in patients with HER2/neu-overexpressing metastatic breast cancer. Semin Oncol 26 (4 Suppl 12): 78–83

    PubMed  CAS  Google Scholar 

  14. Bayo-Calero JL, Mayordomo JI, Sanchez-Rovira P et al. (2008) A phase II study of weekly vinorelbine and trastuzumab in patients with HER2-positive metastatic breast cancer. Clin Breast Cancer 8: 264–268

    Article  PubMed  CAS  Google Scholar 

  15. Berns K, Horlings HM, Hennessy BT et al. (2007) A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell 12: 395–402

    Article  PubMed  CAS  Google Scholar 

  16. Bianchi G, Albanell J, Eiermann W et al. (2003) Pilot trial of trastuzumab starting with or after the doxorubicin component of a doxorubicin plus paclitaxel regimen for women with HER2-positive advanced breast cancer. Clin Cancer Res 9(16 Pt 1): 5944–5951

    PubMed  CAS  Google Scholar 

  17. Bisagni G, Bologna A, Moretti G, Gnoni R (2010) Safety and tolerability of lapatinib in combination with vinorelbine (N) and capécitabine (C) as second line treatment in patients with HER2 positive metastatic breast cancer (MBC). European Society of Medical Oncology 2010, Milan, Italia

    Google Scholar 

  18. Blackwell KL, Burstein HJ, Storniolo AM et al. (2010) Randomized study of Lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol 28: 1124–1130

    Article  PubMed  CAS  Google Scholar 

  19. Blackwell KL, Pegram MD, Tan-Chiu E et al. (2009) Single-agent lapatinib for HER2-overexpressing advanced or metastatic breast cancer that progressed on first-or second-line trastuzumab-containing regimens. Ann Oncol 20: 1026–1031

    Article  PubMed  CAS  Google Scholar 

  20. Burris H, Rodon J, Sharma S et al. (2010) First-in-human phase I study of the oral PI3K inhibitor BEZ235 in patients (pts) with advanced solid tumors. American Society of Clinical Oncology Annual Meeting; 2010; Chicago, US

    Google Scholar 

  21. Burstein HJ, Harris LN, Marcom PK et al. (2003) Trastuzumab and vinorelbine as first-line therapy for HER2-overexpressing metastatic breast cancer: multicenter phase II trial with clinical outcomes, analysis of serum tumor markers as predictive factors, and cardiac surveillance algorithm. J Clin Oncol 21: 2889–2895

    Article  PubMed  CAS  Google Scholar 

  22. Burstein HJ, Storniolo AM, Franco S et al. (2008) A phase II study of lapatinib monotherapy in chemotherapy-refractory HER2-positive and HER2-negative advanced or metastatic breast cancer. Ann Oncol 19: 1068–1074

    Article  PubMed  CAS  Google Scholar 

  23. Burstein HJ, Sun Y, Dirix LY et al. (2010) Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer. J Clin Oncol 28: 1301–1307

    Article  PubMed  CAS  Google Scholar 

  24. Cameron D, Casey M, Press M et al. (2008) A phase III randomized comparison of lapatinib plus capécitabine vs capécitabine alone in women with advanced breast cancer that has progressed on trastuzumab: updated efficacy and biomarker analyses. Breast Cancer Res Treatment 112: 533–543

    Article  CAS  Google Scholar 

  25. Campone M, Conte P, Amadori D et al. (2009) Phase I trial of Panobinostat (LBH589) in combination with trastuzumab in pretreated HER2-positive metastatic breast cancer: preliminary safety, efficacy and pharmacokinetic results. San Antonio Breast Cancer Symposium, 2009; San Antonio, Texas

    Google Scholar 

  26. Cancello G, Montagna E, D’Agostino D et al. (2008) Continuing trastuzumab beyond disease progression: outcomes analysis in patients with metastatic breast cancer. Breast Cancer Res 10: R60

    Article  PubMed  CAS  Google Scholar 

  27. Capri G, Chang J, Chen SC et al. (2010) An open-label expanded access study of lapatinib and capécitabine in patients with HER2-overexpressing locally advanced or metastatic breast cancer. Ann Oncol 21: 474–480

    Article  PubMed  CAS  Google Scholar 

  28. Catania C, Medici M, Magni E et al. (2007) Optimizing clinical care of patients with metastatic breast cancer: a new oral vinorelbine plus trastuzumab combination. Ann Oncol 18: 1969–1975

    Article  PubMed  CAS  Google Scholar 

  29. Chan A (2007) A review of the use of trastuzumab (Herceptin) plus vinorelbine in metastatic breast cancer. Ann Oncol 18: 1152–1158

    Article  PubMed  CAS  Google Scholar 

  30. Chandarlapaty S, Scaltriti M, Angelini P et al. (2010) Inhibitors of HSP90 block p95-HER2 signaling in Trastuzumab-resistant tumors and suppress their growth. Oncogene 29: 325–334

    Article  PubMed  CAS  Google Scholar 

  31. Cheng JQ, Lindsley CW, Cheng GZ, Yang H, Nicosia SV (2005) The Akt/PKB pathway: molecular target for cancer drug discovery. Oncogene 24: 7482–7492

    Article  PubMed  CAS  Google Scholar 

  32. Chia S, Clemons M, Martin LA et al. (2006) Pegylated liposomal doxorubicin and trastuzumab in HER-2 overexpressing metastatic breast cancer: a multicenter phase II trial. J Clin Oncol 24: 2773–2778

    Article  PubMed  CAS  Google Scholar 

  33. Chia SKL, Baetz T, S’Aloisio S et al. (2009) A phase 1 study to assess the safety, tolerability and pharmacokinetics of ARRY-380-an oral inhibitor of HER2. San Antonio Breast Cancer Symposium 2009, San Antonio, Texas

    Google Scholar 

  34. Chow L, Gupta S, Hershman D et al. (2009) Safety and Efficacy of Neratinib (HKI-272) in Combination with Paclitaxel in ErbB2+ Metastatic Breast Cancer. San Antonio Breast Cancer Symposium 2009, SAn Antonio, Texas, US

    Google Scholar 

  35. Cobleigh MA, Vogel CL, Tripathy D et al. (1999) Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 17: 2639–2648

    PubMed  CAS  Google Scholar 

  36. Conlin AK, Seidman AD, Bach A et al. (2010) Phase II trial of weekly nanoparticle albumin-bound paclitaxel with carboplatin and trastuzumab as first-line therapy for women with HER2-overexpressing metastatic breast cancer. Clinical Breast Cancer 10: 281–287

    Article  PubMed  CAS  Google Scholar 

  37. Cortes J, Di Cosimo S, Climent MA et al. (2009) Nonpegylated liposomal doxorubicin (TLC-D99), paclitaxel, and trastuzumab in HER-2-overexpressing breast cancer: a multicenter phase I/II study. Clin Cancer Res 15: 307–314

    Article  PubMed  CAS  Google Scholar 

  38. Crone SA, Zhao YY, Fan L et al. (2002) ErbB2 is essential in the prevention of dilated cardiomyopathy. Nature Med 8: 459–465

    Article  PubMed  CAS  Google Scholar 

  39. Dalenc F, Campone M, Hupperets P et al. (2010) Everolimus in combination with weekly paclitaxel and trastuzumab in patients (pts) with HER2-overexpressing metastatic breast cancer (MBC) with prior resistance to trastuzumab and taxanes: a multicenter phase II clinical trial. ASCO 2010, Chicago, US

    Google Scholar 

  40. Dawood S, Broglio K, Buzdar AU, Hortobagyi GN, Giordano SH (2010) Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review. J Clin Oncol 28: 92–98

    Article  PubMed  CAS  Google Scholar 

  41. Dawood S, Broglio K, Esteva FJ et al. (2008) Defining prognosis for women with breast cancer and CNS metastases by HER2 status. Ann Oncol 19: 1242–1248

    Article  PubMed  CAS  Google Scholar 

  42. De Laurentiis M, Arpino G, Massarelli E et al. (2005) A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer. Clin Cancer Res 11: 4741–4748

    Article  PubMed  Google Scholar 

  43. Di Leo A, Gomez HL, Aziz Z et al. (2008) Phase III, double-blind, randomized study comparing lapatinib plus paclitaxel with placebo plus paclitaxel as first-line treatment for metastatic breast cancer. J Clin Oncol 26: 5544–5552

    Article  PubMed  CAS  Google Scholar 

  44. Dickler M, Franco S, Stopeck A, Ma W, Nulsen B (2008) Final Results From a Phase II Evaluation of Lapatinib (L) and Bevacizumab (B) in HER2-Overexpressing Metastatic Breast Cancer (MBC). San Antonio Breast Cancer Symposium 2008, San Antonio, Texas, US

    Google Scholar 

  45. Dieras V, Kennedy MJ, Tresca P et al. (2010) Open-label, multicenter, phase Ib, dose-escalation study of oral lapatinib (L) in combination with docetaxel (D) and trastuzumab (T) in untreated HER2-overexpressing (HER+) metastatic breast cancer (MBC). American Society of Clinical Oncology 2010, Chicago, US

    Google Scholar 

  46. Dowsett M (2001) Overexpression of HER-2 as a resistance mechanism to hormonal therapy for breast cancer. Endocrine-Related Cancer 8: 191–195

    Article  PubMed  CAS  Google Scholar 

  47. Edelman G, Bedell C, Shapiro G et al. (2010) A phase I dose-escalation study of XL147 (SAR245408), a PI3K inhibitor administered orally to patients (pts) with advanced malignancies. American Society of Clinical Oncology Annual Meeting 2010, Chicago, US

    Google Scholar 

  48. Eichhorn PJ, Gili M, Scaltriti M et al. (2008) Phosphatidylinositol 3-kinase hyperactivation results in lapatinib resistance that is reversed by the mTOR/ phosphatidylinositol 3-kinase inhibitor NVP-BEZ235. Cancer Res 68: 9221–9230

    Article  PubMed  CAS  Google Scholar 

  49. Esteva FJ, Franco S, Hagan MK et al. (2010) Updated efficacy and safety assessment of first-line therapy with lapatinib, trastuzumab, and paclitaxel in HER2+ metastatic breast cancer. ASCO 2010, Chicago, US

    Google Scholar 

  50. Esteva FJ, Guo H, Zhang S et al. (2010) PTEN, PIK3CA, p-AKT, and p-p70S6K status: association with trastuzumab response and survival in patients with HER2-positive metastatic breast cancer. Am J Pathol 177: 1647–1656

    Article  PubMed  CAS  Google Scholar 

  51. Esteva FJ, Valero V, Booser D et al. (2002) Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer. J Clin Oncol 20: 1800–1808

    Article  PubMed  CAS  Google Scholar 

  52. Ewer MS, Lippman SM (2005) Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity. J Clin Oncol 23: 2900–2902

    Article  PubMed  CAS  Google Scholar 

  53. Extra JM, Antoine EC, Vincent-Salomon A et al. (2010) Efficacy of trastuzumab in routine clinical practice and after progression for metastatic breast cancer patients: the observational Hermine study. The Oncologist 15: 799–809

    Article  PubMed  CAS  Google Scholar 

  54. Fabi A, Di Benedetto A, Merola R et al. (2010) Correlation of efficacy between EGFR copy number and lapatinib/capecitabine therapy in HER2-positive metastatic breast cancer. ASCO 2010, Chicago, US

    Google Scholar 

  55. Fabi A, Metro G, Ferretti G et al. (2008) Do HER-2 positive metastatic breast cancer patients benefit from the use of trastuzumab beyond disease progression? A monoinstitutional experience and systematic review of observational studies. Breast (Edinburgh, Scotland) 17: 499–505

    Google Scholar 

  56. Fasolo A, Gianni L, Rorive A et al. (2008) Multicenter phase I clinical trial of daily and weekly RAD001 (everolimus) in combination with vinorelbine and trastuzumab in patients with HER-2-overexpressing metastatic breast cancer with prior resistance to trastuzumab. San Antonio Breast Cancer Symposium 2008, San Antonio, Texas

    Google Scholar 

  57. Franklin MC, Carey KD, Vajdos FF, Leahy DJ, de Vos AM, Sliwkowski MX (2004) Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. Cancer Cell 5: 317–328

    Article  PubMed  CAS  Google Scholar 

  58. Friedman S, Levy R, Garrett W et al. (2009) Clinical Benefit of INCB7839, a Potent and Selective Inhibitor of ADAM10 and ADAM17, in Combination with Trastuzumab in Metastatic HER2 Positive Breast Cancer Patients. San Antonio Breast Cancer Symposium 2009, San Antonio, Texas

    Google Scholar 

  59. Gasparini G, Gion M, Mariani L et al. (2007) Randomized Phase II Trial of weekly paclitaxel alone vs trastuzumab plus weekly paclitaxel as first-line therapy of patients with Her-2 positive advanced breast cancer. Breast Cancer Res Treat 101: 355–365

    Article  PubMed  CAS  Google Scholar 

  60. Gennari A, De Tursi M, Carella C et al. (2009) Epirubicin plus low-dose trastuzumab in HER2 positive metastatic breast cancer. Breast Cancer Res Treat 115: 131–136

    Article  PubMed  CAS  Google Scholar 

  61. Geyer CE, Forster J, Lindquist D et al. (2006) Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med Dec 355: 2733–2743

    Article  CAS  Google Scholar 

  62. Gianni L, Eiermann W, Pusztai l et al. (2008) Biomarkers as potential predictors of pathologic complete response (pCR) in the NOAH trial of neoadjuvant trastuzumab in patients (pts) with HER2-positive locally advanced breast cancer (LABC). ASCO 2008, Chicago, US

    Google Scholar 

  63. Gomez HL, Doval DC, Chavez MA et al. (2008) Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer. J Clin Oncol 26: 2999–3005

    Article  PubMed  CAS  Google Scholar 

  64. Han S, Ro J, Paquet A et al. (2010) HER2, p95HER2, and HER3 expression and treatment outcome of lapatinib plus capécitabine in HER2-positive, trastuzumabrefractory metastatic breast cancer. ASCO 2010, Chicago, US

    Google Scholar 

  65. Heinemann V, Di Gioia D, Vehling-Kaiser U et al. (2011) A prospective multicenter phase II study of oral and i.v. vinorelbine plus trastuzumab as first-line therapy in HER2-overexpressing metastatic breast cancer. Ann Oncol 22: 603–608

    Article  PubMed  CAS  Google Scholar 

  66. Hickish T, Wheatley D, Lin N et al. (2009) Use of BIBW 2992, a novel irreversible EGFR/HER1 and HER2 tyrosine kinase inhibitor to treat patients with HER-2 positive metastatic breast cancer after failure of treatment with trastuzumab. San Antonio Breast Cancer Symposium 2009, San Antonio, Texas

    Google Scholar 

  67. Hiurvitz SA, Pegram MD, Lin LS et al. (2009) Final results of a phase II traial evaluating trastuzumab and bevacizumab as first line treatment of HER2-amplified advanced breast cancer. San Antonio Breast Cancer Symposium 2009, San Antonio, Texas, US

    Google Scholar 

  68. Infante JR, Yardley DA, Burris HA, 3rd et al. (2009) Phase II trial of weekly docetaxel, vinorelbine, and trastuzumab in the first-line treatment of patients with HER2-positive metastatic breast cancer. Clin Breast Cancer 9: 23–28

    Article  PubMed  CAS  Google Scholar 

  69. Inoue K, Nakagami K, Mizutani M et al. (2010) Randomized phase III trial of trastuzumab monotherapy followed by trastuzumab plus docetaxel vs trastuzumab plus docetaxel as first-line therapy in patients with HER2-positive metastatic breast cancer: the JO17360 Trial Group. Breast Cancer Res Treat 119: 127–136

    Article  PubMed  CAS  Google Scholar 

  70. Jackson JG, St Clair P, Sliwkowski MX, Brattain MG (2004) Blockade of epidermal growth factor-or heregulin-dependent ErbB2 activation with the anti-ErbB2 monoclonal antibody 2C4 has divergent downstream signaling and growth effects. Cancer Res 64: 2601–2609

    Article  PubMed  CAS  Google Scholar 

  71. Jahanzeb M, Mortimer JE, Yunus F et al. (2002) Phase II trial of weekly vinorelbine and trastuzumab as first-line therapy in patients with HER2(+) metastatic breast cancer. The Oncologist 7: 410–417

    Article  PubMed  CAS  Google Scholar 

  72. Johnston S, Pippen J, Jr., Pivot X et al. (2009) Lapatinib combined with letrozole vs letrozole and placebo as first-line therapy for postmenopausal hormone receptorpositive metastatic breast cancer. J Clin Oncol 27: 5538–5546

    Article  PubMed  CAS  Google Scholar 

  73. Kaufman B, Mackey JR, Clemens MR et al. (2009) Trastuzumab plus anastrozole vs anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study. J Clin Oncol 27: 5529–5537

    Article  PubMed  CAS  Google Scholar 

  74. Konecny GE, Pegram MD, Venkatesan N et al. (2006) Activity of the dual kinase inhibitor lapatinib (GW572016) against HER-2-overexpressing and trastuzumabtreated breast cancer cells. Cancer Res 66: 1630–1639

    Article  PubMed  CAS  Google Scholar 

  75. Krop I, LoRusso P, Miller KD et al. (2010) A phase 2 study of the HER2 antibodydrug conjugate trastuzumab-DM1 (T-DM1) in patients (pts) with HER2-positive metastatic breast cancer (MBC) previously treated with trastuzumab, lapatinib, and chemotherapy. European Society of Medical Oncology 2010, Milan, Italy

    Google Scholar 

  76. Krop IE, Beeram M, Modi S et al. (2010) Phase I study of trastuzumab-DM1, an HER2 antibody-drug conjugate, given every 3 weeks to patients with HER2-positive metastatic breast cancer. J Clin Oncol 28: 2698–2704

    Article  PubMed  CAS  Google Scholar 

  77. Laughner E, Taghavi P, Chiles K, Mahon PC, Semenza GL (2001) HER2 (neu) signaling increases the rate of hypoxia-inducible factor 1alpha (HIF-1alpha) synthesis: novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mol Cell Biol 21: 3995–4004

    Article  PubMed  CAS  Google Scholar 

  78. Le XF, Mao W, Lu C et al. (2008) Specific blockade of VEGF and HER2 pathways results in greater growth inhibition of breast cancer xenografts that overexpress HER2. Cell Cycle (Georgetown, Tex) 7: 3747–3758

    Google Scholar 

  79. Lewis Phillips GD, Li G, Dugger DL et al. (2008) Targeting HER2-positive breast cancer with trastuzumab-DM1, an antibody-cytotoxic drug conjugate. Cancer Res 68: 9280–9290

    Article  PubMed  CAS  Google Scholar 

  80. Liedtke C, Broglio K, Moulder S et al. (2009) Prognostic impact of discordance between triple-receptor measurements in primary and recurrent breast cancer. Ann Oncol 20: 1953–1958

    Article  PubMed  CAS  Google Scholar 

  81. Lin NU, Carey LA, Liu MC et al. (2008) Phase II trial of lapatinib for brain metastases in patients with human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 26: 1993–1999

    Article  PubMed  CAS  Google Scholar 

  82. Lin NU, Dieras V, Paul D et al. (2009) Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer. Clin Cancer Res 15: 1452–1459

    Article  PubMed  CAS  Google Scholar 

  83. Lin NU, Winer EP (2007) Brain metastases: the HER2 paradigm. Clin Cancer Res 13: 1648–1655

    Article  PubMed  CAS  Google Scholar 

  84. Liu PC, Liu X, Li Y et al. (2006) Identification of ADAM10 as a major source of HER2 ectodomain sheddase activity in HER2 overexpressing breast cancer cells. Cancer Biol & Ther 5: 657–664

    Article  CAS  Google Scholar 

  85. Loesch D, Asmar L, McIntyre K et al. (2008) Phase II trial of gemcitabine/carboplatin (plus trastuzumab in HER2-positive disease) in patients with metastatic breast cancer. Clin Breast Cancer 8: 178–186

    Article  PubMed  CAS  Google Scholar 

  86. Lower EE, Glass E, Blau R, Harman S (2009) HER-2/neu expression in primary and metastatic breast cancer. Breast Cancer Res Treat 113: 301–306

    Article  PubMed  CAS  Google Scholar 

  87. Lu Y, Zi X, Zhao Y, Mascarenhas D, Pollak M (2001) Insulin-like growth factor-I receptor signaling and resistance to trastuzumab (Herceptin). J Nat Cancer Instit 93: 1852–1857

    Article  CAS  Google Scholar 

  88. Marcom PK, Isaacs C, Harris L et al. (2007) The combination of letrozole and trastuzumab as first or second-line biological therapy produces durable responses in a subset of HER2 positive and ER positive advanced breast cancers. Breast Cancer Res Treat 102: 43–49

    Article  PubMed  CAS  Google Scholar 

  89. Marty M, Cognetti F, Maraninchi D et al. (2005) Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J Clin Oncol 23: 4265–4274

    Article  PubMed  CAS  Google Scholar 

  90. McKian KP, Haluska P (2009) Cixutumumab. Expert opinion on investigational drugs. 18: 1025–1033

    Article  PubMed  CAS  Google Scholar 

  91. Meden H, Beneke A, Hesse T, Novophashenny I, Wischnewsky M (2001) Weekly intravenous recombinant humanized anti-P185HER2 monoclonal antibody (herceptin) plus docetaxel in patients with metastatic breast cancer: a pilot study. Anticancer Res 21: 1301–1305

    PubMed  CAS  Google Scholar 

  92. Metro G, Fabi A, Foglietta J et al. (2010) Trastuzumab-based therapy after disease progression following lapatinib and capécitabine in HER2-positive (HER2+) metastatic breast cancer (MBC). European Society of Medical Oncology 2010, Milan, Italia

    Google Scholar 

  93. Metro G, Foglietta J, Russillo M et al. (2011) Clinical outcome of patients with brain metastases from HER2-positive breast cancer treated with lapatinib and capecitabine. Ann Oncol 22: 625–630

    Article  PubMed  CAS  Google Scholar 

  94. ussillo M, Milella M, Cognetti F, Fabi A (2007) Clinical utility of continuing trastuzumab beyond brain progression in HER-2 positive metastatic breast cancer. The Oncologist 12: 1467–1469; author reply 9–71

    Article  Google Scholar 

  95. Michalaki V, Fotiou S, Gennatas S, Gennatas C (2010) Trastuzumab plus capécitabine and docetaxel as first-line therapy for HER2-positive metastatic breast cancer: phase II results. Anticancer Res 30: 3051–3054

    PubMed  CAS  Google Scholar 

  96. Migliaccio I, Gutierrez M, Wu M, Wong H (2008) PI3 kinase activation and response to trastuzumab or lapatinib in HER-2 overexpressing locally advanced breast cancer (LABC). San Antonio Breast Cancer Symposium 2008, San Antonio, Texas, US

    Google Scholar 

  97. Miller K, Gianni L, André F et al. (2010) A phase Ib/II trial of trastuzumab-DM1 (T-DM1) with pertuzumab (P) for women with HER2-positive, locally advanced or metastatic breast cancer (BC) who were previously treated with trastuzumab (T). ASCO 2010; Chicago, US

    Google Scholar 

  98. Miller TW, Forbes JT, Shah C et al. (2009) Inhibition of mammalian target of rapamycin is required for optimal antitumor effect of HER2 inhibitors against HER2-overexpressing cancer cells. Clin Cancer Res 15: 7266–7276

    Article  PubMed  CAS  Google Scholar 

  99. Modi S, Stopeck A (2006) Phase II trial of trastuzumab and KOS-953 (tanespimycin) in patients with HER2-positive breast cancer: Preliminary results. Breast Cancer Res Treat 100: S72(Suppl 1): Abstrast 1102

    Google Scholar 

  100. Modi S, Stopeck AT, Gordon MS et al. (2007) Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study. J Clin Oncol 25: 5410–5417

    Article  PubMed  CAS  Google Scholar 

  101. Molina MA, Codony-Servat J, Albanell J, Rojo F, Arribas J, Baselga J (2001) Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells. Cancer Res 61: 4744–4749

    PubMed  CAS  Google Scholar 

  102. Montemurro F, Choa G, Faggiuolo R et al. (2004) A phase II study of three-weekly docetaxel and weekly trastuzumab in HER2-overexpressing advanced breast cancer. Oncology 66: 38–45

    Article  PubMed  CAS  Google Scholar 

  103. Morrow PH, Wulf GM, Booser DJ et al. (2010) Phase I/II trial of everolimus (RAD001) and trastuzumab in patients with trastuzumab-resistant, HER2 overexpressing breast cancer. ASCO 2010, Chicago, US

    Google Scholar 

  104. Nagata Y, Lan KH, Zhou X et al. (2004) PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 6: 117–127

    Article  PubMed  CAS  Google Scholar 

  105. Nagy P, Friedlander E, Tanner M et al. (2005) Decreased accessibility and lack of activation of ErbB2 in JIMT-1, a herceptin-resistant, MUC4-expressing breast cancer cell line. Cancer Res 65: 473–482

    PubMed  CAS  Google Scholar 

  106. Nahta R, Esteva FJ (2006) HER2 therapy: molecular mechanisms of trastuzumab resistance. Breast Cancer Res 8: 215

    Article  PubMed  CAS  Google Scholar 

  107. Nahta R, Hung MC, Esteva FJ (2004) The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells. Cancer Res 64: 2343–2346

    Article  PubMed  CAS  Google Scholar 

  108. Nahta R, Yuan LX, Du Y, Esteva FJ (2007) Lapatinib induces apoptosis in trastuzumab-resistant breast cancer cells: effects on insulin-like growth factor I signaling. Mol Cancer Ther 6: 667–674

    Article  PubMed  CAS  Google Scholar 

  109. Nahta R, Yuan LX, Zhang B, Kobayashi R, Esteva FJ (2005) Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells. Cancer Res 65: 11118–1128

    Article  PubMed  CAS  Google Scholar 

  110. Negro A, Brar BK, Lee KF (2004) Essential roles of Her2/erbB2 in cardiac development and function. Recent Progr Horm Res 59: 1–12

    Article  PubMed  CAS  Google Scholar 

  111. Nistico C, Bria E, Vaccaro V et al. (2009) Trastuzumab plus weekly epirubicin and paclitaxel for locally advanced and metastatic breast cancer: preliminary results of a feasibility-phase II study aimed at cardiotoxicity. Anti-Cancer Drugs 20: 109–114

    Article  PubMed  CAS  Google Scholar 

  112. O’Brien NA, Browne BC, Chow L et al. (2010) Activated phosphoinositide 3-kinase/ AKT signaling confers resistance to trastuzumab but not lapatinib. Mol Cancer Ther 9: 1489–1502

    Article  PubMed  CAS  Google Scholar 

  113. O’Shaughnessy JA, Vukelja S, Marsland T, Kimmel G, Ratnam S, Pippen JE (2004) Phase II study of trastuzumab plus gemcitabine in chemotherapy-pretreated patients with metastatic breast cancer. Clin Breast Cancer 5: 142–147

    Article  PubMed  Google Scholar 

  114. Park YH, Park MJ, Ji SH et al. (2009) Trastuzumab treatment improves brain metastasis outcomes through control and durable prolongation of systemic extracranial disease in HER2-overexpressing breast cancer patients. Br J Cancer 100: 894–900

    Article  PubMed  CAS  Google Scholar 

  115. Pegram M, Yeon C, Ku N (2004) Phase I Combined Biological Therapy of Breast Cancer Using Two Humanized Monoclonal Antibodies Directed Against HER2 Proto-Oncogene and Vascular Endothelial Growth Factor (VEGF). San Antonio Breast Cancer Symposium 2004, San Antonio, Texas, US

    Google Scholar 

  116. Pegram MD, Pienkowski T, Northfelt DW et al. (2004) Results of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancer. J Nat Cancer Instit 96: 759–769

    Article  CAS  Google Scholar 

  117. Pegram MD, Slamon DJ (1999) Combination therapy with trastuzumab (Herceptin) and cisplatin for chemoresistant metastatic breast cancer: evidence for receptorenhanced chemosensitivity. Semin Oncol 26 (4 Suppl 12): 89–95

    PubMed  CAS  Google Scholar 

  118. Perez EA, Dirix L, Kocsis J et al. (2010) Efficacy and safety of trastuzumab-DM1 vs trastuzumab plus docetaxel in HER2-positive metastatic breast cancer patients with no prior chemotherapy for metastatic disease: preliminary results of a randomized, multicenter, open-label phase 2 study (TDM4450G). European Society of Medical Oncology 2010, Milan, Italy

    Google Scholar 

  119. Perez EA, Koehler M, Byrne J, Preston AJ, Rappold E, Ewer MS (2008) Cardiac safety of lapatinib: pooled analysis of 3689 patients enrolled in clinical trials. Mayo Clinic Proceedings. 83: 679–686

    PubMed  Google Scholar 

  120. Perez EA, Suman VJ, Rowland KM et al. (2005) Two concurrent phase II trials of paclitaxel/carboplatin/trastuzumab (weekly or every-3-week schedule) as first-line therapy in women with HER2-overexpressing metastatic breast cancer: NCCTG study 983252. Clin Breast Cancer 6: 425–432

    Article  PubMed  CAS  Google Scholar 

  121. Petruzelka LB, Ganju V, Becquart D et al. (2010) Phase II study of the combination of oral vinorelbine (NVBo), capécitabine (X), and trastuzumab (H) in HER2-positive, metastatic breast cancer (MBC): recent analysis of the results with a median follow-up of 44 months. ASCO 2010, Chicago, US

    Google Scholar 

  122. Portera CC, Walshe JM, Rosing DR et al. (2008) Cardiac toxicity and efficacy of trastuzumab combined with pertuzumab in patients with corrected] human epidermal growth factor receptor 2-positive metastatic breast cancer. Clin Cancer Res 14: 2710–2716

    Article  PubMed  CAS  Google Scholar 

  123. Presta LG, Chen H, O’Connor SJ et al. (1997) Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 57: 4593–4599

    PubMed  CAS  Google Scholar 

  124. Qadir Z, Crown J, Jensen MR, Clynes M, Slamon D (2010) HSP90 inhibition in HER2-positive breast cancer cells. ASCO 2010, Chicago, US

    Google Scholar 

  125. Rabindran SK, Discafani CM, Rosfjord EC et al. (2004) Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase. Cancer Res 64: 3958–3965

    Article  PubMed  CAS  Google Scholar 

  126. Raja SM, Clubb RJ, Bhattacharyya M et al. (2008) A combination of Trastuzumab and 17-AAG induces enhanced ubiquitinylation and lysosomal pathway-dependent ErbB2 degradation and cytotoxicity in ErbB2-overexpressing breast cancer cells. Cancer Biol & Therapy 7: 1630–1640

    Article  CAS  Google Scholar 

  127. Rasmussen BB, Regan MM, Lykkesfeldt AE et al. (2008) Adjuvant letrozole vs tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial. Lancet Oncol 9: 23–28

    Article  PubMed  CAS  Google Scholar 

  128. Robert N, Leyland-Jones B, Asmar L et al. (2006) Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer. J Clin Oncol 24: 2786–2792

    Article  PubMed  CAS  Google Scholar 

  129. Ruiz M, Salvador J, Bayo J et al. (2008) Phase-II study of weekly schedule of trastuzumab, paclitaxel, and carboplatin followed by a week off every 28 days for HER2+ metastatic breast cancer. Cancer Chemother Pharmacol 62: 1085–1090

    Article  PubMed  CAS  Google Scholar 

  130. Santinelli A, Pisa E, Stramazzotti D, Fabris G (2008) HER-2 status discrepancy between primary breast cancer and metastatic sites. Impact on target therapy. Intern J Cancer 122: 999–1004

    Article  CAS  Google Scholar 

  131. Sato N, Sano M, Tabei T et al. (2006) Combination docetaxel and trastuzumab treatment for patients with HER-2-overexpressing metastatic breast cancer: a multicenter, phase-II study. Breast Cancer (Tokyo, Japan) 13: 166–171

    Article  Google Scholar 

  132. Saura C, Martin M, Moroose R et al. (2009) Safety of Neratinib (HKI-272) in Combination with Capécitabine in Patients with Solid Tumors: A Phase 1/2 Study. San Antonio Breast Cancer Symposium 2009, San Antonio, Texas, US

    Google Scholar 

  133. Sawyer DB, Zuppinger C, Miller TA, Eppenberger HM, Suter TM (2002) Modulation of anthracycline-induced myofibrillar disarray in rat ventricular myocytes by neuregulin-1beta and anti-erbB2: potential mechanism for trastuzumab-induced cardiotoxicity. Circulation 105: 1551–1554

    Article  PubMed  CAS  Google Scholar 

  134. Scaltriti M, Chandarlapaty S, Prudkin L et al. (2010) Clinical benefit of lapatinibbased therapy in patients with human epidermal growth factor receptor 2-positive breast tumors coexpressing the truncated p95HER2 receptor. Clin Cancer Res 16: 2688–2695

    Article  PubMed  CAS  Google Scholar 

  135. Scaltriti M, Rojo F, Ocana A et al. (2007) Expression of p95HER2, a truncated form of the HER2 receptor, and response to anti-HER2 therapies in breast cancer. J Natl Cancer Instit 99: 628–638

    Article  CAS  Google Scholar 

  136. Schaller G, Fuchs I, Gonsch T et al. (2007) Phase II study of capécitabine plus trastuzumab in human epidermal growth factor receptor 2 overexpressing metastatic breast cancer pretreated with anthracyclines or taxanes. J Clin Oncol 25: 3246–3250

    Article  PubMed  CAS  Google Scholar 

  137. Scheuer W, Friess T (2006) Enhanced Antitumour Effect by Combination of HER2-Targeting Antibodies With Bevacizumab in a Human Breast Cancer Xenograft Model. 18th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics 2006, Prague, Czech Republic

    Google Scholar 

  138. Seidman A, Hudis C, Pierri MK et al. (2002) Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 20: 1215–1221

    Article  PubMed  CAS  Google Scholar 

  139. Seidman AD, Berry D, Cirrincione C et al. (2008) Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840. J Clin Oncol 26: 1642–1649

    Article  PubMed  CAS  Google Scholar 

  140. Seidman AD, Fornier MN, Esteva FJ et al. (2001) Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification. J Clin Oncol 19: 2587–295

    PubMed  CAS  Google Scholar 

  141. Slamon D, Gomez HL, Kabbinavar FF et al. (2008) Randomized study of pazopanib + lapatinib vs. lapatinib alone in patients with HER2-positive advanced or metastatic breast cancer. ASCO, 2008

    Google Scholar 

  142. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL (1987) Human breast cancer: correlation of relapse and survival with amplification of the HER-2/ neu oncogene. Science (New York, NY) 235: 177–182

    Article  CAS  Google Scholar 

  143. Slamon DJ, Leyland-Jones B, Shak S et al. (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. New Engl J Med 344: 783–792

    Article  PubMed  CAS  Google Scholar 

  144. Solit D, Basso AD, Smith-Jones P (2005) Inhibitors of Hsp90 induce the degradation of HER-2 and inhibit the growth of HER-2 dependent breast tumors. San Antonio Breast Cancer Symposium 2005, San Antonio, Texas

    Google Scholar 

  145. Spazzapan S, Crivellari D, Tumolo S (2010) Retreatment with trastuzumab after progression on lapatinib-based therapy in heavily pretreated HER2-positive metastatic breast cancer: a monoinstitutional experience. ASCO 2010, Chicago

    Google Scholar 

  146. Spector NL, Blackwell KL (2009) Understanding the mechanisms behind trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 27: 5838–5847

    Article  PubMed  CAS  Google Scholar 

  147. Sperduti I, Cuppone F, Vaccaro V et al. (2010) Meta-analysis of randomized clinical trials exploring single agent chemotherapy vs multi-agent chemotherapy in addition to trastuzumab for HER-2-overexpressing advanced breast cancer: what is the most appropriate comparator? European Society of Medical Oncology 2010, Milan, Italia

    Google Scholar 

  148. Stickeler E, Klar M, Watermann D et al. (2009) Pegylated liposomal doxorubicin and trastuzumab as 1st and 2nd line therapy in her2/neu positive metastatic breast cancer: a multicenter phase II trial. Breast Cancer Res Treat 117: 591–598

    Article  PubMed  CAS  Google Scholar 

  149. Storniolo AM, Magrinat G, Rubin P et al. (2009) A Phase I, Dose Escalation Study of Lapatinib in Combination with Carboplatin, Paclitaxel, with or without Trastuzumab in Patients with Metastatic Breast Cancer: An Update. San Antonio Breast Cancer Symposium 2009, San Antonio, Texas, US

    Google Scholar 

  150. Suter T, Brammer M, Ross G (2009) Pooled Analysis of Cardiac Safety in Patients Treated with Pertuzumab. San Antonio Breast Cancer Symposium 2009, San Antonio, Texas, US

    Google Scholar 

  151. Suter TM, Cook-Bruns N, Barton C (2004) Cardiotoxicity associated with trastuzumab (Herceptin) therapy in the treatment of metastatic breast cancer. Breast (Edinburgh, Scotland) 13: 173–183

    CAS  Google Scholar 

  152. Suter TM, Procter M, van Veldhuisen DJ et al. (2007) Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial. J Clin Oncol 25: 3859–3865

    Article  PubMed  CAS  Google Scholar 

  153. Swaby R, Blackwell K, Jiang Z et al. (2009) Neratinib in combination with trastuzumab for the treatment of advanced breast cancer: A phase I/II study. American Society of Clinical Oncology Annual Meeting 2009, Chicago, US

    Google Scholar 

  154. Tedesco KL, Thor AD, Johnson DH et al. (2004) Docetaxel combined with trastuzumab is an active regimen in HER-2 3+ overexpressing and fluorescent in situ hybridization-positive metastatic breast cancer: a multi-institutional phase II trial. J Clin Oncol 22: 1071–1077

    Article  PubMed  CAS  Google Scholar 

  155. Theodoulou M, Batist G, Campos S, Winer E, Welles L, Hudis C (2009) Phase I study of nonpegylated liposomal doxorubicin plus trastuzumab in patients with HER2-positive breast cancer. Clin Breast Cancer 9: 101–107

    Article  PubMed  CAS  Google Scholar 

  156. Tolaney SM, Najita J, Chen W et al. (2008) A phase II study of ixabepilone plus trastuzumab for metastatic HER2-positive breast cancer. San Antonio Breast Cancer Symposium 2008, San Antonio

    Google Scholar 

  157. Untch M, Muscholl M, Tjulandin S et al. (2010) First-line trastuzumab plus epirubicin and cyclophosphamide therapy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: cardiac safety and efficacy data from the Herceptin, Cyclophosphamide, and Epirubicin (HERCULES) trial. J Clin Oncol 28: 1473–1480

    Article  PubMed  CAS  Google Scholar 

  158. Venturini M, Bighin C, Monfardini S et al. (2006) Multicenter phase II study of trastuzumab in combination with epirubicin and docetaxel as first-line treatment for HER2-overexpressing metastatic breast cancer. Breast Cancer Res Treat 95: 45–53

    Article  PubMed  CAS  Google Scholar 

  159. Venturini M, Bighin C, Puglisi F et al. (2010) A multicentre Phase II study of nonpegylated liposomal doxorubicin in combination with trastuzumab and docetaxel as first-line therapy in metastatic breast cancer. Breast (Edinburgh, Scotland) 19: 333–338

    CAS  Google Scholar 

  160. Vogel CL, Cobleigh MA, Tripathy D et al. (2002) Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 20: 719–726

    Article  PubMed  CAS  Google Scholar 

  161. von Minckwitz G, du Bois A, Schmidt M et al. (2009) Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study. J Clin Oncol 27: 1999–2006

    Article  CAS  Google Scholar 

  162. Vukelja S, Rugo H, Vogel C et al. (2008) A phase II study of trastuzumab-DM1, a first-in-class HER2 antibody-drug conjugate, in patients with HER2+ metastatic breast cancer. San Antonio Breast Cancer Symposium 2008, San Antonio, Texas

    Google Scholar 

  163. Wardley AM, Pivot X, Morales-Vasquez F et al. (2010) Randomized phase II trial of first-line trastuzumab plus docetaxel and capecitabine compared with trastuzumab plus docetaxel in HER2-positive metastatic breast cancer. J Clin Oncol 28: 976–983

    Article  PubMed  CAS  Google Scholar 

  164. Yakes FM, Chinratanalab W, Ritter CA, King W, Seelig S, Arteaga CL (2002) Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action. Cancer Res 62: 4132–4141

    PubMed  CAS  Google Scholar 

  165. Yamamoto D, Iwase S, Kitamura K, Odagiri H, Yamamoto C, Nagumo Y (2008) A phase II study of trastuzumab and capécitabine for patients with HER2-overexpressing metastatic breast cancer: Japan Breast Cancer Research Network (JBCRN) 00 Trial. Cancer Chemother Pharmacol 61: 509–514

    Article  PubMed  CAS  Google Scholar 

  166. Yap TA, Vidal L, Adam J et al. (2010) Phase I trial of the irreversible EGFR and HER2 kinase inhibitor BIBW 2992 in patients with advanced solid tumors. J Clin Oncol 28: 3965–3972

    Article  PubMed  CAS  Google Scholar 

  167. Yardley DA, Seiler M, Ray-Coquard I et al. (2009) Ridaforolimus (AP23573; MK-8669) in Combination with Trastuzumab for Patients with HER2-Positive Trastuzumab-Refractory Metastatic Breast Cancer: A Multicenter Phase 2 Clinical Trial. San Antonio Breast Cancer Symposium 2009, San Antonio, Texas

    Google Scholar 

  168. Yardley DA, Daniel D, Stipanov M et al. (2010) A phase II trial of oxaliplatin and trastuzumab in the treatment of HER2-positive metastatic breast cancer. Cancer Invest 28: 865–871

    Article  PubMed  CAS  Google Scholar 

  169. Yardley DA, McCleod M, Schreiber F et al. (2010) A phase II trial of vinflunine as monotherapy or in combination with trastuzumab as first-line treatment of metastatic breast cancer. Cancer Invest 28: 925–931

    Article  PubMed  CAS  Google Scholar 

  170. Yokoi A, McCrudden KW, Huang J et al. (2003) Blockade of her2/neu decreases VEGF expression but does not alter HIF-1 distribution in experimental Wilms tumor. Oncology Reports 10: 1271–1274

    PubMed  CAS  Google Scholar 

Download references

Authors
  1. S. Guiu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. B. Coudert
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. P. Fumoleau
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

Copyright information

© 2012 Springer-Verlag France, Paris

About this paper

Cite this paper

Guiu, S., Coudert, B., Fumoleau, P. (2012). Anti-HER2 et cancers du sein métastatiques: Résultats cliniques des anti-HER2 actuels et futurs. In: Cancer du sein. Springer, Paris. https://doi.org/10.1007/978-2-8178-0245-9_33

Download citation

  • DOI: https://doi.org/10.1007/978-2-8178-0245-9_33

  • Publisher Name: Springer, Paris

  • Print ISBN: 978-2-8178-0244-2

  • Online ISBN: 978-2-8178-0245-9

Publish with us

Policies and ethics

Search

Navigation